EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Gefitinib is dramatically effective for nonsmall cell lung cancers (NSCLCs) with activating mutations of the epidermal growth factor receptor (EGFR) gene, but these tumors eventually develop drug resistance, attributable to a secondary T790M mutation or acquired MET amplification in some relapsed tumors. We analyzed EGFR mutations in matched pre‐ and post‐therapeutic tumors of 6 gefitinib‐responding lung cancers. With conventional PCR‐based sequencing, classic mutations were detected in pretreatment samples of each case. The same mutations were readily confirmed in treated lesions of 4 cases, but were absent in those of Cases 1 and 2. Subsequent mutant‐enriched peptide‐nucleic‐acid‐mediated PCR clamping and subcloning assays detected the mutation in minor cells of treated lesions of Case 1, but still failed to detect a mutation in Case 2. We thus performed microdissection‐based cell cluster mutation analysis of pretreatment tumors, and found that 3, including the first 2, concurrently contained tumor cells with either mutant or wild‐type EGFR, although the latter was only a minor fraction. These findings suggest that some NSCLCs are genetically heterogeneous with regard to EGFR mutations; gefitinib‐sensitive mutants decrease or vanish while wild clones selectively survive with gefitinib treatment. In addition, T790M was detected in a small fraction of treated lesions of 3 cases, and MET amplification was revealed in 3 treated tumors of Case 2. Thus, our results suggest that multiple mechanisms underlie acquired gefitinib resistance, and selection on a background of EGFR genetic heterogeneity also contributes to acquisition of resistance in a proportion of NSCLCs. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517 · cited 1×
“Initial phase II trials have shown that 20% of nonsmall cell lung cancer (NSCLC) patients respond dramatically to gefitinib and erlotinib.(1,2) The striking clinical responses were subsequently shown to be associated with somatic activating mutations consisting mainly of small in-frame deletions and missense substitut…”
BackgroundBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · cited 10×
“MET amplification was thought to be a counteraction against the cellular survival pressure conferred by inhibition of EGFR in TKI-treated NSCLCs.23,24 It is noticeable that MET amplification was detected in treated lesions of Case 2, in which the original EGFR L861Q mutation was no longer detectable.”
BackgroundResultInfluentialOncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
Cited by
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
“Besides a secondary T790M mutation (41) and acquired MET amplification (42), selection of an EGFR wild-type subpopulation on a background of wild-type/mutant mixture leads to acquired EGFR-TKI resistance in NSCLC (43).”
BackgroundInfluentialLindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 462
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296
Moores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Thunnissen, E., Kerr, K. M., Herth, F. J. F., Lantuejoul, S., Papotti, M., Rintoul, R. C., Rossi, G., Skov, B. G., Weynand, B., Bubendorf, L., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.017 · Cited by 228
Yang, J. J., Zhou, Q., Yan, H. H., Zhang, X. C., Chen, H. J., Tu, H. Y., Wang, Z., Xu, C. R., Su, J., Wang, B. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.456 · Cited by 175
Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., Yang, J.-J., Zhou, Q., Yan, H.-H., An, S.-J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0385 · Cited by 165
“This phenomenon may be explained by heterogeneity in the EGFR mutation status between the primary lung tumors and their metastases [10, 11].”
BackgroundT790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · PubMed · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82
Metadata
- Authors
- Jiang, S., Yamashita, K., Yamamoto, M., Piao, C., Umezawa, A., Saegusa, M., Yoshida, T., Katagiri, M., Masuda, N., Hayakawa, K., & Okayasu, I.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-09-10
- Volume
- 123
- Issue
- 11
- Pages
- 2480-2486
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2079778947
- Cited by
- 78
- References
- 6
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.